OncoMatch/Clinical Trials/NCT05857969

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Is NCT05857969 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Functional Precision Medicine for recurrent childhood acute myeloid leukemia.

Treatment: Functional Precision Medicine — Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.